No phaseRecruiting
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
- Sponsor
- Washington University School of Medicine (Academic or other)
- Enrolment
- 100 planned
- Conditions
- Whole Genome Sequencing; Myelodysplastic Syndromes
- Interventions
- ChromoSeq
- Ages
- adults, older adults
- Registry
- NCT05434598
Full record on ClinicalTrials.gov
From the registry
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnosis of myelodysplastic syndrome (MDS).
Primary outcomes
- Rate of assay success on first attempt compared between ChromoSeq and conventional cytogenetics as measured by total number of recurrent structural variants identified
- Rate of assay success on first attempt compared between ChromoSeq and conventional cytogenetics as measured by total number of copy number alterations identified
- Proportion of failed ChromoSeq assays
- IPSS-M risk score compared between ChromoSeq and conventional standard of care genomic profiling (Arm 2 only)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered